IP Library Granted Patent US 10,682,370
Granted Patent B2
US 10,682,370 · App. 14/774,627 · Granted Jun 16, 2020

Topical antiviral composition containing a local anesthetic and method of making the same

Inventors: Je Phil Ryoo (Princeton, NJ); Chun Kwong Chu (Hong Kong, CN)
Assignee: NAL PHARMACEUTICAL GROUP LIMITED
A61K31/7072A61K9/0014A61K9/06A61K31/167A61K45/06A61K47/02A61K47/10A61K47/14A61K47/16A61K47/26A61K47/32A61K47/38A61K47/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,682,370
App. No.
14/774,627
Granted
Jun 16, 2020
Kind
B2
Abstract

The present invention provides a novel pharmaceutical composition and method of making the same. The composition comprises an effective amount of an antiviral agent and a local anesthetic. The antiviral drug can be sorivudine. The local anesthetic can be lidocaine or its pharmaceutically acceptable salt. Herpes virus infections in humans can be caused by different human herpes viruses, the most common being herpes simplex virus types 1 and 2 (HSV1 and HSV2) and varicella-zoster virus (VZV).

Claims (20)

1. A pharmaceutical composition for topical administration consisting of:

an antiviral drug which is sorivudine,

a local anesthetic selected from the group consisting of lidocaine and its pharmaceutically acceptable salt,

sucrose stearate,

polysorbate 80,

sorbitan monooleate,

glycerol,

ethanol,

water,

cetylalcohol,

octadecanol,

caprylic capric triglyceride,

dimethicone, and

glyceryl monostearate,

wherein the range of the antiviral drug sorivudine is from about 1% to about 5% w/wt, wherein the range of the local anesthetic lidocaine and its pharmaceutically acceptable salt is from about 1% to about 6% wt/wt, and wherein the pH of the composition is from about 4.0 to about 4.5.

2. The pharmaceutical composition of claim 1 , wherein the range of the antiviral drug sorivudine is from about 2% to about 4% wt/wt.

3. The pharmaceutical composition of claim 1 , wherein the range of the local anesthetic lidocaine and its pharmaceutically acceptable salt is from about 2% to about 5% wt/wt.

4. The pharmaceutical composition of claim 1 , wherein the antiviral drug is sorivudine 5% and the local anesthetic is lidocaine 5%; the antiviral drug is sorivudine 3% and the local anesthetic is lidocaine 5%; or the antiviral drug is sorivudine 3% and the local anesthetic is lidocaine 2%.

5. A cream, lotion, gel or ointment, solution, liniment, suspension, lacquer, spray, a topical patch, transdermal patch, hydrogel patch, matrix patch, reservoir patch, electrophoresis patch or micro-needle patch containing a pharmaceutical composition of claim 1 .

6. A method for treating herpes virus infections of the skin and pain associated therewith comprising topically applying the pharmaceutical composition of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2016
From: NAL PHARMACEUTICALS, LTD.
To: NAL PHARMACEUTICAL GROUP LIMITED
Reel/Frame 038357/0068 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2016
From: CHU, CHUN KWONG; RYOO, JE PHIL
To: NAL PHARMACEUTICALS, LTD.
Reel/Frame 038175/0891 →
Continuity (2)
Provisional Application 61780041 · Mar 13, 2013
Related Publication 20160015731A1 · Jan 21, 2016